Amylyx Pharmaceuticals, Inc.
NASDAQAmylyx Pharmaceuticals heads into its August 6 earnings report with the most prominent recent signal coming from the analyst community, not the short-selling camp. Citigroup raised its price target on AMLX to $26 from $20 yesterday, maintaining a Buy rating — a move that arrives just one session before the print and resets the immediate-term reference point for bulls. The broader…
Snapshot as of 4 Aug 2026
Amylyx Pharmaceuticals heads into its August 6 earnings report with the most prominent recent signal coming from the analyst community, not the short-selling camp. Citigroup raised its price target on AMLX to $26 from…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for AMLX — free to start on ORTEX.
Sign up for free →Open AMLX on ORTEX